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A B S T R A C T
One of the important tasks of the German Senate Commission for the Investigation of Health Hazards of
Chemical Compounds in the Work Area (known as the MAK Commission) is in the evaluation of a potential for
carcinogenicity of hazardous substances at the workplace. Often, this evaluation is critically based on data on
carcinogenic responses seen in animal studies and, if positive tumor responses have been observed, this will
mostly lead to a classification of the substance under investigation into one of the classes for carcinogens.
However, there are cases where it can be demonstrated with a very high degree of confidence that the tumor
findings in the experimental animals are not relevant for humans at the workplace and, therefore, the MAK
Commission will not classify the respective substance into one of the classes for carcinogens. This paper will
summarize the general criteria used by the MAK Commission for the categorization into “carcinogen” and “non-
carcinogen” and compare this procedure with those used by other national and international organizations.
1. Introduction
The German MAK commission has established five categories for the
classification of carcinogenic chemicals in the work area. Generally,
substances that have been found to be human carcinogens are classified
in Category 1, while those substances that have proven to be carcino-
genic in animal studies are classified in Category 2. Suspected carci-
nogens are classified in Category 3. Up to 1990 the Commission clas-
sified substances according to their carcinogenic hazard for man. Since
the Commission has a long tradition of evaluating the mechanism of
action as part of its assessment procedure, two additional Categories (4
and 5) of carcinogens were introduced in the late 1990s to account for
findings related to the mechanism of carcinogenicity and the dose- and
time-dependence of the carcinogenic effect (Greim, 1999, 2000; 2006a;
Neumann et al., 1998). These new Categories include substances with
carcinogenic properties for which there is sufficient data available to
allow for an assessment of their carcinogenic potency. Substances
classified in Category 4 are known to act via non-genotoxic mechanisms
and genotoxic effects play no or only a minor role at levels that do not
exceed the MAK and BAT values. Under these circumstances, the sub-
stance is not expected to add to the cancer risk of humans.Classification
is based in addition to the results of the carcinogenicity studies on
findings on the (primary) mechanism of action, for example an increase
in cell proliferation, delayed apoptosis or impaired differentiation. Both
the classification category and the MAK and BAT values take into ac-
count the wide range of mechanisms that may contribute to carcino-
genicity and their characteristic dose–time–response relationships.
Carcinogens, which are genotoxic, but of weak potency at and below
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the MAK and BAT values, are classified in Category 5. A more precise
definition of each of the categories can be found in the Annex.
Epidemiological studies are an important source for information on
a potential carcinogenic risk associated with a certain exposure.
However, such studies are often not available or may be difficult to
interpret for various reasons, such as e.g. mixed exposure to more than
just one chemical. Therefore, where human data are not available,
animal studies on the carcinogenic effect of a substance play an im-
portant role in classifying the substance as carcinogenic or non-carci-
nogenic. However, not all positive tumor tests in animals can be judged
as relevant for humans. There are, for example, mechanisms of action
that are specific to a certain animal species, but are absent in humans,
at least under realistic exposure conditions. This is of particular prac-
tical importance for non-genotoxic mechanisms of action, since geno-
toxic carcinogens are generally considered to be relevant for humans
and classified in one of the categories for carcinogens by the German
MAK Commission (see above).
The purpose of this paper is to develop a general guidance for use by
the MAK Commission to evaluate tumor findings from animal studies on
a case-by-case basis, to determine their relevance for humans and to
decide whether a substance should be classified in one of the carci-
nogen categories.
The following key points are identified in this guidance document:
1. Determination of the primary mechanisms of action underlying the
carcinogenicity:
(a) Classification of the mechanisms of action as genotoxic vs. non-
genotoxic
(b) Assessment of the identified mechanisms with respect to their
relevance for humans.
2. Characterization of the dose/time–response relationships of tumor
formation, including the assessment of their relevance for actual
scenarios of human exposure.
3. Assessment of the human relevance of tumors induced only in cer-
tain species and animal strains or in organs not found in humans (as
an example: forestomach tumors in rats).
4. Evaluation of the human relevance of substance-induced cancer
precursors such as adenomas and the characterization of their risk to
develop into malignancy.
Examples of substances evaluated by the MAK Commission are
provided throughout the paper. In addition, in chapter 7 some in-
structive cases are discussed that, despite having yielded positive tumor
findings in animal studies, were not classified in one of the carcinogen
categories by the Commission as well as others classified into Category
4 after thorough analysis and review of experimental findings.
2. Approaches used by other national and international
organizations
The CLP criteria for classification used by the European Chemicals
Agency (ECHA, 2017), the Preamble published by the IARC (Interna-
tional Agency for Research on Cancer; IARC, 2006) and the guidelines
used by the U.S. EPA (U.S. Environmental Protection Agency; U.S. EPA,
2005) all explicitly include the analysis of possible mechanisms of
tumor formation in the assessment of carcinogenicity. All organizations
emphasize the importance of careful evaluation by expert judgments
(ECHA, 2017; IARC, 2006; U.S. EPA, 2005; WHO (Boobis et al., 2006;
Sonich-Mullin et al., 2001)).
2.1. SCOEL
The Scientific Committee on Occupational Exposure Limits for
Chemical Agents (SCOEL) has classified chemical carcinogens into four
groups, namely A, B, C and D, according to the mode of action (Bolt and
Huici-Montagud, 2008; SCOEL, 2017). Thus, clearly DNA-reactive
genotoxic carcinogens and/or those compounds which have the po-
tential to initiate DNA reactivity are grouped in A or B, depending on
the degree of evidence; here, a health-based threshold cannot be es-
tablished. Group C comprises other DNA-reactive genotoxic carcino-
gens, which are only weakly genotoxic and their carcinogenicity ap-
pears to arise from other mechanisms, such as sustained local tissue
damage and increased cell proliferation; here, a “practical” or “ap-
parent” threshold can be established. Finally, chemical agents that are
non-DNA reactive and act on the chromosomal level alone in the ab-
sence of gene mutations are grouped in D. A respective Mode of Action
(MoA) includes the induction of numerical chromosomal aberrations,
and given the existence of sufficient data a threshold concentration can
be established below which the substance is not considered to be car-
cinogenic. SCOEL may also conclude that the available toxicokinetic
and mechanistic evidence does not provide evidence of any MoA or
internal exposure that is of relevance to workers (SCOEL, 2017). The
concept of a “mode of action based threshold” for carcinogens was also
emphasized within the joint task force between SCOEL and the ECHA
Committee for Risk Assessment (RAC) (ECHA/RAC-SCOEL, 2017), and
will be applied by ECHA/RAC after the termination of the SCOEL
committee in February 2019.
2.2. ECHA
According to the CLP criteria for classification of the European
Chemicals Agency, substances which have induced benign and malig-
nant tumors in well performed experimental studies on animals are
considered to be proven or suspected human carcinogens unless there is
strong evidence that the mechanism of tumor formation is not relevant
for humans. Genotoxicity, cytotoxicity with growth stimulation, mito-
genesis and immunosuppression are listed as mechanisms of tumor
formation with human relevance. If there is unequivocal evidence that a
mechanism of tumor formation is not relevant to humans, such as the
α2u-globulin-mediated mechanism that induces renal tumors in male
rats, the substance is not classified as a carcinogen. If tumors are in-
duced only in one sex of an animal species, it must carefully be assessed
whether the development of these tumors is consistent with the pos-
tulated mechanism of tumor formation. Tumors observed in animal
studies in tissues that lack a human equivalent are examined in light of
the overall tumor response, i.e. the incidence of tumors in other organs.
This requires a meticulous expert judgment on the assumed mechanism
of tumor formation (ECHA, 2017).
2.3. IARC
The Preamble of the IARC (International Agency for Research on
Cancer) highlights the importance of determining the relevance of the
mechanism of tumor formation for humans. To clarify the mechanism
of action, changes in the affected organs, tissues or cells caused by
exposure are analyzed at three levels: changes in physiology, functional
changes on the cellular level and changes at the molecular level.
Physiological changes refer to exposure-related modifications to the
physiology and/or response of cells, tissues and organs such as mito-
genesis, inflammation, hyperplasia and metaplasia. Functional changes
refer to exposure-related alterations in the signaling pathways used by
cells to manage critical processes that are related to increased risk for
cancer, for example alterations in cyclin-dependent kinases that govern
cell cycle progression and changes in gap-junction-mediated inter-
cellular communication. Molecular changes refer to exposure-related
changes in key cellular structures at the molecular level, which are
essentially related to genetic integrity, such as DNA strand breaks,
mutations in genes or chromosomal aberrations. The studies of geno-
toxicity are described in view of the relevance of gene mutations and
chromosomal aberrations/aneuploidy to carcinogenesis. If applicable,
other relevant mechanistic data are included in the evaluation such as
structure–activity relationships and data from gene expression
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microarrays. An overview of the possible mechanisms of tumor for-
mation is provided and discussed together with data on toxicokinetics
and other data (IARC, 2006).
2.4. U.S. EPA
In the absence of sufficient, scientifically justifiable information on
the mechanism of tumor formation, the U.S. EPA takes a protective
default position regarding the interpretation of toxicological and epi-
demiological data. Therefore, in the absence of data on the mechanism
of action, animal tumor findings are judged to be relevant to humans.
The U.S. EPA prepared a framework as a tool for evaluating a me-
chanism of carcinogenic action hypothesized for a substance. Modified
Bradford-Hill criteria can be useful for organizing thinking about as-
pects of causation. For the analysis of the mechanism of action, all re-
levant studies are evaluated based on the weight of evidence method,
which points out strengths, weaknesses and uncertainties and discusses
possible alternative conclusions. The mechanism of action is analyzed
for all tumor types observed; this includes a description of the hy-
pothesized mechanism of action as well as the sequence of key events.
The relevance of a possible mechanism of action is evaluated within the
context of a hazard assessment and not in regard to the level of risk.
Human exposure data are therefore not included in the evaluation of
the relevance of a hypothesized mechanism of action (U.S. EPA, 2005).
2.5. WHO – IPCS framework
The IPCS (International Programme on Chemical Safety) framework
of the WHO (World Health Organization) is an approach used to eval-
uate the relevance of a mechanism of carcinogenic action in animals for
humans. The individual steps of this framework are based on Bradford-
Hill criteria of causality, which were originally developed for the in-
terpretation of epidemiological studies (Hill, 1965). These include: 1.
postulated mechanism of action, 2. key events; associated critical
parameters, 3. dose–response relationships, 4. temporal association, 5.
strength, consistency and specificity of association of key events and
tumor response, 6. biological plausibility and coherence, 7. possible
alternative mechanisms of action, 8. uncertainties, inconsistencies and
data gaps, 9. assessment of mechanism of action (Boobis et al., 2006;
Sonich-Mullin et al., 2001).
2.6. Summary
In the absence of sufficient evidence that the mechanism of tumor
formation is not relevant to humans, IARC, ECHA, U.S. EPA and WHO
consider tumor findings from animal studies to be applicable to hu-
mans. However, a critical examination is carried out to determine
whether tumors are induced in only one or in several organs or in only
one or in several species and whether the tumors themselves are re-
levant to humans. Benign tumors that are assumed to progress into
malignant tumors are generally also included in the evaluation. In ad-
dition, the U.S. EPA includes a formalized framework for the assessment
of hypothesized mechanisms of carcinogenesis in the method it uses to
evaluate cancer formation.
A summary of the carcinogenicity classifications of the examples
described in Section 7 by the above mentioned organizations is given in
Table 3. The U.S. EPA is not included in the table because the sub-
stances under concern are not listed by the agency or were not eval-
uated regarding their carcinogenicity.
2.6.1. Advisory and legal concerns
The carcinogen classifications of the MAK Commission are advisory
in nature comparable to those of the IARC. However, even though the
MAK proposals are not directly legally binding they form the scientific
basis for setting legally binding exposure limits by respective regulatory
authorities in Germany and other countries.
US EPA is a regulatory agency authorized by Congress. The Toxic
Substances Control Act (TSCA) of 1976 provides US EPA with authority
to require reporting, record-keeping and testing protocols and to im-
pose restrictions relating to chemical substances and/or mixtures.
The Committee for Risk Assessment (RAC) prepares the opinions of
European Chemicals Agency (ECHA) related to the risks of substances
to human health and the environment in the following REACH
(Registration, Evaluation, Authorisation and Restriction of Chemicals)
and CLP (Classification, Labelling and Packaging of substances and
mixtures) processes. The final decisions are taken by the European
Commission.
The Scientific Committee on Occupational Exposure Limits (SCOEL)
assisted from 1995 to 2018 the European Commission to evaluate the
potential health effects of occupational exposure to chemicals. The
health-based scientific recommendations were used to underpin the
regulatory initiatives on occupational exposure limit values for the
protection of workers from chemical risks.
3. Evaluation of the quality of an experimental study
Before an experimental study is considered to be included into
toxicological decision making by the MAK Commission, it is always
necessary to assess the validity of its study design and of the conclusions
drawn from the results of the study. Other organizations have already
addressed this issue. Guidelines have been published on study design
including the use of the proper study protocol and the selection of
appropriate doses. Some examples are: The OECD Guideline for the
testing of chemicals, here TG 451, “Carcinogenicity Studies” (OECD,
2018), the guidance document for the National Toxicology program
(NTP) for the conduct of animal toxicity/carcinogenicity studies (NTP,
2011), the ICH Topic S1C(R2) “Dose Selection for Carcinogenicity
Studies of Pharmaceuticals” (EMEA, 2008), “Guidance for Industry.
Carcinogenicity Study Protocol Submissions” (FDA, 2002). There are
also guidelines on validation and interpretation, such as the “Guidance
for Industry. Statistical Aspects of the Design, Analysis, and Inter-
pretation of Chronic Rodent Carcinogenicity Studies of Pharmaceu-
ticals” (ECHA, 2017; FDA, 2001; Huff and Haseman, 1991; IARC, 2006;
U.S. EPA, 2005; see also Section 2).
4. Mechanisms with no or only minor human relevance
The following chapter discusses mechanisms that lead to tumor
formation in test animals, but have no or only minor human relevance.
There are several different scenarios.
1. The carcinogenic effect of a particular test chemical is mechan-
istically linked to a very high dose used in the respective animal
study. If this type of exposure cannot occur for humans under rea-
listic conditions, even as a worst-case scenario, the findings obtained
are regarded as not relevant for classification (discussed in Section
4.1 and 4.2).
2. The mechanism of tumor induction is based on parameters that
differ strongly between humans and animals. This may be the case,
for example, for differences in the metabolic competence of tox-
ifying and detoxifying enzymes. In general, according to the
guidelines of the MAK Commission, this would lead to the classifi-
cation of the substance in the relevant Carcinogen Category (CC).
However, the differences between humans and animals may be so
large that, after careful consideration, the more plausible alternative
may be not classifying the respective substance in one of the cate-
gories for carcinogens (discussed in Section 4.3).
3. Furthermore, a number of mechanisms of tumor formation have a
very high species, strain or gender specificity and are thus not re-
levant to humans (discussed in Chapter 5 ).
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4.1. MTD (maximally tolerated dose) and high dose effects
4.1.1. Definition of the MTD
The highest dose of a substance that may be tested in long-term
carcinogenicity studies as stipulated by regulatory authorities is called
the MTD. As the name itself indicates, this is a limit range. The most
commonly used definition of the MTD can be found in the National
Cancer Institute (NCI) publication by Sontag et al. (1976): “The MTD is
defined as the highest dose of the test agent during the chronic study
that can be predicted not to alter the animals' normal longevity from
effects other than carcinogenicity.” This was applied as the basis for
selecting the doses used in carcinogenicity studies carried out by the
NCI and the National Toxicology Program (NTP). In 1976, it was sug-
gested that the dose chosen as the MTD should be one that, in a sub-
chronic study, causes no more than a 10% weight decrement, as com-
pared to the appropriate control groups, and does not produce
mortality, clinical signs of toxicity or pathologic lesions (other than
those that may be related to a neoplastic response) that would be
predicted (in the long-term study) to shorten an animal's natural life-
span (Haseman, 1985). In carcinogenicity studies carried out according
to the test guidelines of the OECD, the MTD is defined as the highest
dose to produce toxic effects “without causing death and to decrease
body weight gain by no more than 10% relative to controls”. The MTD
is used to decide whether the highest dose tested was adequate to give
confidence in a negative result (OECD, 2012).
4.1.2. MTD tumor findings
The MTD as the highest dose tested in long-term carcinogenicity
studies was deliberately chosen for toxicological assessments to ensure
that all carcinogenic effects would be reported, even those that would
generally not be observed due to statistical limitations in the small
animal cohorts that are typically used in long-term carcinogenicity
studies. However, MTD findings are increasingly coming under criti-
cism because non-specific high-dose effects may yield “positive” re-
sponses that are not predictive of lower exposure levels (Ames and
Gold, 1990; Carr and Kolbye, 1991; Greim and Albertini, 2012). This
may cause carcinogenic effects and other associated effects that are not
of importance in low dose ranges that are relevant to humans. In these
cases, the decision not to classify a substance has to be based on the
mechanism of action that is effective in the high dose range of the
substance, but is not evident at lower levels of exposure, even in animal
studies. For this reason, it must be carefully assessed in each case
whether “MTD findings” are relevant for the classification of that sub-
stance as carcinogen.
Indeed, a large number of substances have been found to be carci-
nogenic at extremely high doses in animal studies that would not have
been classified as carcinogens at lower doses. An evaluation of the re-
sults of the carcinogenicity studies in rats and mice, which was de-
scribed in the 1989 Carcinogenic Potency Database (CPDB), concluded
that 492 of 975 investigated substances, i.e. almost half of the sub-
stances, caused carcinogenic effects in at least one study (Gold et al.,
1989). This can be explained by the fact that, for decades, the results of
animal studies with very high doses (up to the MTD) have been used for
the evaluation of carcinogenicity. The rationale was to increase the
sensitivity of tests that were carried out with a limited number of ani-
mals. However, as early as in 1990, it was suspected that this approach
leads to an overestimation of the “hazard” presented to humans by low,
non-cytotoxic doses of carcinogens. The administration of substances at
doses close to the MTD is postulated to increase mitogenesis (e.g. by
stimulating regenerative growth), which in turn increases rates of
mutagenicity and, thus, carcinogenicity (Ames and Gold, 1990). This
may explain why 50% of all natural and synthetic pesticides tested in
these studies showed a carcinogenic effect (Ames et al., 1990). The
suitability of rodent carcinogenicity studies for predicting human
cancer risk is also being critically debated in the pharmaceutical sector
(Alden et al., 2011; Anisimov et al., 2005; Sistare et al., 2011).
In conclusion, the relevance of tumor findings from animal studies
after exposure to high doses for predicting the tumor response at low
doses, which are relevant to humans, needs to be critically examined
(Greim and Albertini, 2012, 2015) with respect to high-dose effects
such as “metabolic overloading” and “secondary carcinogenesis” (e.g.
induced by toxic regenerative responses). However, in individual cases,
this requires clear evidence that the respective mechanisms do not arise
after exposure to concentrations that are relevant to humans, i.e. that
human exposure occurs at levels far below the dose that may lead to a
carcinogenic response (Haseman, 1985).
A question that is frequently asked concerns the human relevance of
tumors that are observed in animal studies only close to the MTD. In
these cases, the causative mechanism needs to be determined (Slikker
et al., 2004a, b). The substance should in general not be classified as
carcinogenic if it can unequivocally be ascertained that the mechanism
that is effective in the high dose range close to the MTD qualitatively
does not occur at lower doses and is therefore not relevant for exposure
at the workplace even in worst case scenarios. In this case, the effect
threshold has a mechanistic basis that can clearly be defined and used
as a reason for non-classification.
Examples are biguanide derivatives. In two carcinogenicity studies
(unpublished studies, ICI America Inc. and AstraZeneca, respectively),
polyhexamethylene biguanide given to mice in the diet at the very
high dose of 4000mg/kg diet (males: 715mg/kg body weight and day;
females: 856mg/kg body weight and day) induced vascular tumors
(hemangiosarcomas). These were in the range of the historical controls
at a middle dose of 1200mg/kg diet. At the high dose, mortality was
increased and body weights were reduced by 35%–42% in males and by
22%–33% in females, despite increased food consumption. As bigua-
nides impair glucose utilization, they are used in anti-diabetic thera-
pies. The effect is induced by reduced glucose absorption in the intes-
tine and the suppression of gluconeogenesis and ATP production (ECHA
RAC, 2011). Impaired mitochondrial oxidative phosphorylation leads to
reduced ATP synthesis. Similar to cellular hypoxia, this leads to the
activation of hypoxia-inducible factors (HIFs), which regulate a large
number of cellular functions such as the transcription of the hormone
erythropoietin (EPO). EPO stimulates the proliferation of red blood
cells, promotes the vascular endothelial growth factor (VEGF), which
regulates angiogenesis, and induces glycolytic enzymes (Tormos and
Chandel, 2010). A consequence in mice is the induction of vascular
tumors, which is, however, a typical “high dose effect”. In humans,
even a single dose at this high level would change glucose metabolism
so dramatically that neither short-term nor long-term exposure at this
level would be tolerated. Long-term exposure at the level that induces
tumors in mice is therefore not possible in humans. In addition, sub-
stance-induced hemangioadenomas and hemangiosarcomas are ex-
tremely rare in humans. They have only been observed after high-level
exposure of workers to vinyl chloride and in patients who received
thorotrast (as a radiocontrast agent) for diagnostic purposes (Cohen
et al., 2009). In summary, the tumors observed in mice after long-term
exposure to biguanides are not relevant for classification because ex-
posure of humans to a tumor-inducing dose is not possible; glucose
metabolism will have been completely disrupted long before this level
of exposure is reached. This is an example of a case in which the tu-
morigenic effect of a substance cannot be induced in humans under
normal circumstances because of the limitation of the dose resulting
from acute toxicity.
In the high dose range of the MTD, cytotoxic effects may also lead to
“indirect genotoxic” effects that can initiate and accelerate the process
of carcinogenesis. A key role plays the generation of reactive oxygen
and nitrogen species (ROS and RNS, respectively) that may be initiated
at very high doses by processes such as uncoupling of the mitochondrial
respiratory chain (Filser et al., 2008; Wiseman and Halliwell, 1996).
However, this does not mean that ROS and RNS are only induced in the
high dose range. Increased ROS and RNS formation may play a role at
low levels of exposure that are relevant to humans, for example as the
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result of Fenton or Fenton-like reactions catalyzed by a transition metal
or as the result of inflammatory reactions induced by xenobiotics. For
this reason, the human relevance of these types of “indirect genotoxic”
effects has to be assessed on a case-by-case basis.
However, in many cases, the decision against classifying substances
with positive tumor findings in animal studies in a Carcinogen Category
cannot be based on mechanistic considerations. Under these circum-
stances, it is prudent to classify the substances in one of the categories
for carcinogenic substances (generally in CC 4) and to indicate a MAK
value, below which an exposure is regarded as being safe. Obviously,
there is a gray area in which the decision for classification or non-
classification has to be weighed carefully based on the established
criteria.
4.2. Importance of species-specific differences in the activities of xenobiotic-
metabolizing enzymes
The chronic toxicity and carcinogenicity of most carcinogens with
human relevance is dependent upon the activity of toxifying and de-
toxifying enzyme systems, which can vary strongly between different
species, both quantitatively and qualitatively. For this reason, it is im-
portant to take into consideration the species-specific enzyme systems
that activate metabolic pathways, and their associated toxification and
detoxification processes.
One example is an extremely efficient process in the liver of mice
that involves the inactivation of the active metabolite of aflatoxin B1,
the 8,9-epoxide, by an isoform of glutathione S-transferase. In con-
sequence, mice are resistant to the hepatocarcinogenic effect of afla-
toxin B1. Neither rats nor humans have a similarly efficient detoxifying
enzyme (Degen and Neumann, 1981) and therefore are, unlike the
mouse, highly susceptible to this hepatocarcinogen.
Another example that has been investigated extensively is styrene
and the species-specific detoxification capacity towards its metabolite
styrene-7,8-oxide, which has a direct alkylating effect, by microsomal
epoxide hydrolase in the liver. Among the analyzed species, the activity
of this enzyme is lowest in the mouse and then increases in the order
mouse < rat < human (Mendrala et al., 1993; Seidegård et al., 1986).
For this reason, styrene caused lung tumors only in mice, but not in rats
(Greim, 2003a; IARC, 2002; NRC, 2014). Body burden levels de-
termined by toxicokinetic investigations carried out in different species
to assess the carcinogenic risk for humans have shown that changes in
metabolic parameters in rats, mice and humans lead to similar changes
in styrene and styrene-7,8-oxide concentrations in the blood. However,
according to a physiologically based pharmacokinetic model, marked
changes in the styrene-7,8-oxide concentrations in the blood of mice
exposed by inhalation to styrene concentrations of 500ml/m3 were
predicted because at this exposure concentration, glutathione-S-trans-
ferase (GST)-dependent detoxification of styrene-7,8-oxide has practi-
cally stopped functioning in the mouse due to the complete depletion of
glutathione stores. Styrene-7,8-oxide concentrations in the blood thus
reach a concentration that is high enough to saturate the elimination
process for styrene-7,8-oxide by a second enzyme, epoxide hydrolase.
For this reason, a slight increase in styrene-7,8-oxide will exceed the
detoxification capacity of epoxide hydrolase, causing the alkylating
agent to accumulate disproportionately. In contrast, a slight increase in
the maximal activity of epoxide hydrolase would lead to a more effi-
cient detoxification of styrene-7,8-oxide, thereby compensating for the
loss of the glutathione-dependent pathway. Therefore, in mice, slight
changes to the balance of styrene-7,8-oxide production and elimination
through repeated administration drastically change the body burden
levels of styrene-7,8-oxide. This phenomenon does not occur in rats and
humans because of their higher epoxide hydrolase activity (Csanády
et al., 1994), which means that mice are more sensitive to styrene ex-
posure. In addition, there is a further plausible mechanistic explanation
for the formation of lung tumors observed exclusively in styrene-ex-
posed mice. In this species, lung metabolism of styrene is primarily
mediated by the cytochrome P450 (CYP) 2F2 isoform, which is found in
the Clara cells. The corresponding CYP2F4 in rats and CYP2F1 in hu-
mans and primates have a far lower metabolic capacity. In mice,
CYP2F2 mediates not only styrene-7,8-oxide formation but also the
formation of ring-hydroxylated epoxide derivatives, which cause cyto-
toxicity in Clara cells leading to regenerative hyperplasia and ulti-
mately lung tumors (Cruzan et al., 2009, 2013). Based on the ob-
servations regarding species-specific differences in metabolism, it is
likely that the assumed mechanism in the Clara cells in mice is not
relevant to human lung cells to a biologically significant extent. How-
ever, the impact of circulating styrene-7,8-oxide and DNA adducts such
as O6-deoxyguanosine-(O6-(2-hydroxy-1-phenylethyl)-2′-deoxyguano-
sine-3′-monophosphate) and N7-deoxyguanosine adducts observed in
workers needs to be taken into account and may potentially play a role
in organs other than the lung (IARC, 2002). Therefore, based on the
data on the cancer risk for humans, the substance was classified in CC 5
(Greim, 2003a).
A general guideline cannot be established for the decision whether a
substance should be classified in CC 4 or whether classification is not
required. It will always be made on a case-by-case basis. In cases of
uncertainty, a “conservative” approach should be followed with clas-
sification in CC 4 or in another carcinogen category if it is not possible
to derive a MAK or BAT value.
4.3. Specific mechanisms of tumor formation that are not relevant to
humans (see Table 1)
4.3.1. α2u-globulin-mediated kidney effects
Renal tubule tumors in male rats are one example that has under-
gone extensive investigation; these tumors are induced via the α2u-
globulin-mediated mechanism. α2u-globulin is synthesized only in the
liver of male rats, but not in the livers of female rats or other species
(IARC, 1999b; Swenberg, 1993). The carcinogenic mechanism involves
the binding of substances to this protein, leading to their accumulation
in the kidney. This elicits cytotoxicity, which in turn induces a re-
generative response in the form of cell proliferation. Clear evidence of
this mechanism is provided by the following facts: lack of genotoxic
activity of the substance and its metabolites; male rat specificity for
nephropathy and renal tumorigenicity; verification of accumulation of
α2u-globulin in renal cells; demonstration of the presence of a specific
characteristic sequence of histopathological changes in short-term stu-
dies, of which protein droplet accumulation is obligatory; similarities in
dose-response relationship of the tumor outcome with the histopatho-
logical end points (α2u-globulin accumulation, protein droplets and
cell proliferation) and the reversible binding of the substance or me-
tabolite to α2u-globulin (IARC, 1999a, b). In the adverse outcome
pathway leading to the formation of kidney tumors in male rats, α2u-
globulin plays a key role. The non-relevance of this mechanism for
humans was ultimately concluded from the fact that this protein is not
produced in humans, which means that this very well described tumor
induction pathway is not applicable. Substances that induce these kinds
of tumors in animals are, for example, decahydronaphthalene
(Hartwig, MAK Commission, 2016a), d-limonene (Greim, 2006b,
available only in German) and 2,2,4-trimethylpentane (Hartwig,
2014a).
4.3.2. Tumors resulting from precipitate formation in the efferent urinary
tract
Data available on sodium saccharide, sodium ascorbate (Note: no
MAK documentations available) and terephthalic acid (Hartwig,
2009a) suggest that epithelial tumors of the bladder in rats are induced
by the formation of a precipitate in the urine leading to cytotoxicity and
increased regenerative cell proliferation. The most important indication
for this assumption is that tumors can form only at urine concentrations
at which the solubility product is exceeded. If critical concentration
levels are not reached, the precipitate that can induce carcinogenicity
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does not form. In addition, there are important interspecies differences
in the composition of the urine (protein concentration, total density and
osmolarity) between rats and humans which affect the formation of
precipitates or calculi (IARC, 1999b, d). Therefore, and because of the
limitation of the carcinogenic effects to the high-dose range and the
marked differences in the sensitivity of the epithelium of the efferent
urinary tract between humans and rats, the corresponding tumors of the
transitional epithelium are not considered relevant to humans as long
as inflammatory or reactive alterations in the urothelium are not in-
duced (Edler et al., 2014).
An example is tributyl phosphate, which was evaluated by the
MAK Commission in 2000. Long-term studies reported local cell da-
mage with reversible hyperplastic, proliferative and necrotic changes in
the bladder of rats. Papillomas and, especially in the male animals,
transitional cell carcinomas are found as a result of the damage to the
bladder. These effects are not expected in humans at concentrations as
long as inflammatory effects are not induced. Therefore, the MAK
Commission has classified this substance as a carcinogen with a
threshold in CC 4. (Greim, 2002b).
In the case of o-phenylphenol (OPP), the MAK Commission con-
cluded in 2016 that questions still remained as to the human relevance
of the hyperplasia, papillomas and transitional cell carcinomas of the
bladder observed in male F344 rats. The induction mechanism of cell
proliferation has not completely been elucidated for OPP; the effects
were, however, observed in the saturation range of metabolism. The pH
of the urine or calculi alone was not considered the decisive factor in
the formation of urothelial carcinomas (Hartwig, MAK Commission,
2016b, available only in German). For this reason, the substance has
been classified in CC 4.
Mesenchymal tumors of the mouse bladder develop from the lamina
propria, a layer of connective tissue that lies beneath the epithelium.
Bifenthrin, a synthetic pyrethroid (Note: no MAK documentation
available), is an example of a substance that induces mesenchymal
tumors in the mouse bladder which is a non-invasive benign pro-
liferation mainly in the submucosa (Butler et al., 1997). Up until this
point, no tumor that originates in the submucosa (lamina propria) and
is morphologically similar to the submucosal mesenchymal tumors of
the mouse bladder has been described in humans. This type of tumor is
not known to occur in other animal species. The following expert
evaluation by Cohen (2011) is well accepted among scientists and
government authorities: this type of bladder tumor seen in high-dose
males that exceeded the MTD is mouse-specific, is not a carcinoma, is
not invasive, does not metastasize, generally arises from inflammatory
disorders and is without relevance to human.
4.3.3. Pheochromocytomas resulting from hypoxia
Pheochromocytomas originate in the chromaffin cells of the adrenal
medulla. Induction of hypoxia is a common underlying mechanism,
resulting, e.g., from impaired breathing, pulmonary toxicity or the
uncoupling of oxidative phosphorylation (Greim et al., 2009; Ozaki
et al., 2002). Inhalation studies with poorly soluble substances such as
talc (NTP, 1993), nickel (II) oxide (NTP, 1996a), nickel subsulfide
(NTP, 1996b), cobalt sulfate heptahydrate (NTP, 1998), gallium
arsenide (NTP, 2000) and indium phosphide (NTP, 2001) suggest
that there is a possible relationship between marked hypoxic conditions
in the lungs (with the formation of fibrosis, inflammation and pul-
monary tumors) and the formation of pheochromocytoma. Cobalt and
nickel have also been shown to inhibit HIF1α (hypoxia-inducible factor
1α) degradation, thereby adapting cellular metabolism to oxygen de-
ficient conditions (Greim et al., 2009).
The development of pheochromocytomas in animal studies under
toxic conditions is assessed as a secondary effect that is of little re-
levance for conditions at the workplace. Pheochromocytomas rarely
occur in humans, with about 30% caused by genetic factors. Up to now,
there is no indication that substances that cause pheochromocytomas in
animal studies also induce these tumors in humans. (Greim et al.,
2009). Furan is an example of a substance that was not classified into a
carcinogen category by the MAK Commission despite animal studies
that yielded positive findings of pheochromocytoma (Greim, 2006c).
Although the pheochromocytomas observed in animal studies are
not considered relevant to classification because of their mechanism of
induction, this does not mean that substances that lead to the formation
of these tumors in animal studies can generally be absolved of being
carcinogenic risk factors. In fact, the above-mentioned metals are strong
carcinogens (as shown by epidemiological data in the case of nickel
(classified in CC 1) and by animal studies in the case of cobalt (classified
in CC 2); in case of the latter, a recent NTP study also provides evidence
of carcinogenicity in rats even after exposure to very low concentra-
tions (NTP, 2016). Gallium arsenide was also classified in CC1 by the
MAK Commission on the basis of its metabolites, which have been
shown to be genotoxic and carcinogenic (Hartwig, 2014b). Generally,
these metals induce - in addition to hypoxia - effects that are of human
relevance and occur at concentrations that are much more realistic for
humans. Of particular importance in this regard are indirect genotoxic
mechanisms such as interference with DNA repair processes, tumor
suppression functions, etc. (Beyersmann and Hartwig, 2008).
Table 1
Specific tumor formation in test animals, without or with only minor human relevance.
Mechanism Tumor (Species) Examples of substances
α2u-globulin-mediated adenomas and carcinomas of the renal tubules (male rat) decahydronaphthalene, D-limonene, 2,2,4-
trimethylpentane
formation of precipitates in the urine urothelial adenomas and carcinomas of the bladder (rat) sodium saccharine, sodium ascorbate,
terephthalic acid
higher sensitivity of the epithelium of the efferent urinary tract of
male rats
carcinomas of the transitional epithelium of the bladder
(male rat)
o-phenylphenol
proliferation of the mesothelium of the bladder of male mice mesenchymal tumors including sarcomas of the bladder
originating in the lamina propria (male mouse)
bifenthrin
hypoxia, uncoupling of oxidative phosphorylation pheochromocytoma of the adrenal medulla (male rat) furan
changes to thyroid hormone homeostasis through induction of
glucuronosyltransferases or inhibition of peroxidases
follicular thyroid adenomas (rat) spironolactone, sulfamethazine,
thiabendazole
mediated by agonists of dopamine and GnRH Leydig cell adenomas (male rats/mice) nicotine
modulation of the dopaminergic tonus at dopamine D1 and D2
receptors or other membrane proteins
mesothelioma of the tunica vaginalis testis (male F344
rats)
acrylamide, methyl eugenol
PPARα-mediated liver adenomas and liver carcinomas (rat, mouse) clofibrate, trichloroacetic acid
severe irritation caused by non-DNA-reactive irritant substances after
administration by gavage
forestomach, papillomas and squamous cell carcinomas
(rat/mouse)
butylated hydroxyanisole (BHA)
lack of the respective organ in humans Zymbal's gland, squamous cell carcinomas (rat) chlorodifluoromethane
lack of the respective organ in humans Harderian gland, adenomas/carcinomas (rat) nitromethane
CYP: cytochrome P450; GnRH: gonadotropin-releasing hormone; PPARα: Peroxisome Proliferator Activated Receptor α.
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4.3.4. Tumors of the thyroid gland caused by induction of
glucuronosyltransferases
Adenomas can be caused by increased TSH (thyroid stimulating
hormone) levels in the thyroid gland of rats, which stimulate the
function of the thyroid gland and thus lead to thyroid proliferative
changes. Increased TSH levels can be caused by the induction of glu-
curonosyltransferases, which accelerate thyroxine (T4) clearance and
reduce triiodothyronine (T3) levels. Spironolactone is an example of a
substance mediating its carcinogenic effect in the thyroid gland of rats
through induction of glucuronosyltransferases in liver. Another ex-
ample is thiabendazole, which induces a slight, but statistically sig-
nificant increase in thyroid adenomas in Sprague Dawley rats, but not
in F344 rats. This is again related to the induction of glucuronosyl-
transferases. Accordingly, the substance has not been classified in one
of the categories for carcinogens (Hartwig, 2009b, available only in
German). An increase in TSH levels can also be caused more directly by
the inhibition of thyroid peroxidase by substances such as sulfa-
methazine. Non-genotoxic substances such as spironolactone and sul-
famethazine are not carcinogenic in humans as long as they do not
disrupt thyroid hormone homeostasis (IARC, 2001).
Humans are less sensitive to disturbances in thyroid hormone
homeostasis than rats. Adult humans have an efficient store of T3 and
T4 by means of iodinated thyreoglobulin, which is present in very large
amounts in the colloid of the thyroid, and can maintain the supply of T3
and T4 for several months even if hormone synthesis is disrupted. In
contrast, rats have only a limited storage capacity. In addition, humans
have a transport protein for T3 and T4 available in the form of the
thyroxine-binding globulin, which considerably prolongs the half-life of
thyroid hormones in the blood as compared to rats, where the hor-
mones are bound exclusively to albumin. A T3 deficiency induced by
xenobiotics in rats thus very quickly stimulates TSH synthesis, thereby
promoting the growth of the thyroid gland (Bartsch et al., 2018). As this
mechanism has practically no relevance for humans, thyroid tumors
induced in rats by the above-mentioned mechanisms are generally not
considered relevant to humans and do not lead to classification by the
MAK Commission.
4.3.5. Leydig cell tumors mediated by agonists of dopamine and GnRH
Leydig cell tumors induced in male rats and mice by effects medi-
ated by agonists of dopamine and GnRH (gonadotropin-releasing hor-
mone) are not considered relevant to humans. This is because GnRH
and prolactin receptors are either not expressed or are expressed only at
very low levels in the testes of humans. By contrast, other mechanisms
that cause Leydig cell tumors are relevant to humans, such as the in-
hibition of testosterone biosynthesis, 5α-reductase and aromatase or
estrogen agonism (Cook et al., 1999; RIVM, 2004).
4.3.6. Dopamine receptor mediated mesothelioma of the tunica vaginalis
testis
A substance-induced increase in the incidence of mesothelioma of
the tunica vaginalis testis was observed only in male F344 rats, but not
in other rat strains (Sprague Dawley, Osborne Mendel and Wistar) or in
B6C3F1 mice (Shipp et al., 2006). During the formation of spontaneous
tunica vaginalis mesothelioma and several forms of substance-induced
tunica vaginalis mesothelioma, autocrine growth factors induce mitosis
in mesothelial cells. Methyl eugenol is one example (Maronpot et al.,
2009). The assumed mechanism for the formation of tunica vaginalis
mesothelioma, the modulation of the dopaminergic tonus at dopamine
D1 and D2 receptors or other membrane proteins, which leads to an
acceleration of age-dependent hormonal changes in male F344 rats, is
not considered relevant to humans (Shipp et al., 2006).
4.3.7. PPARα-mediated liver tumors
Liver adenomas and carcinomas, which are only formed in rats and
mice via processes mediated by the peroxisome proliferator activated
receptor α (PPARα), are not considered relevant to humans. However,
this type of assessment requires the exclusion of other mechanisms of
carcinogenicity in addition to evidence of peroxisome proliferation and
hepatocellular proliferation under the experimental conditions of car-
cinogenicity studies (IARC, 1994, 1996; RIVM, 2003). The response of
the human liver to PPARα ligands is qualitatively and quantitatively
different from the response seen in the livers of rats and mice. Evidence
suggests that this is due to marked differences in PPARα-mediated gene
regulation (different target genes, different receptor activities and dif-
ferent receptor levels) (Klaunig et al., 2003). Similar effects on per-
oxisomes were found neither in adequate studies in humans nor in
human cells (IARC, 1994, 1996). Peroxisome proliferation was not
observed in PPARα-humanized mice exposed to the prototype PPARα
agonist Wy-14643 and, unlike wild-type mice, these mice did not de-
velop hepatocellular carcinomas (Morimura et al., 2006).
The key events are the activation of PPARα, perturbation of cell
proliferation and apoptosis, selective clonal expansion and a series of
associative events involving peroxisome proliferation, hepatocyte oxi-
dative stress and Kupffer-cell mediated events (Klaunig et al., 2003).
Besides clofibrate (Note: no MAK documentation available), another
example is trichloroacetic acid (Hartwig, MAK Commission, 2016c,
available only in German). Trichloroacetic acid induces liver adenomas
and carcinomas in B6C3F1 mice. The substance has been found to be a
strong PPARα agonist and peroxisome proliferator. The level of per-
oxisome proliferation has been correlated with the total number of
tumors per animal. Trichloroacetic acid was not classified in any of the
categories for carcinogens because of the high spontaneous incidence of
liver tumors in B6C3F1 mice and the mechanism of action that has no
human relevance.
4.3.8. Effects after non-physiological routes of administration
Non-physiological administration of a test substance may com-
pletely change its toxicokinetics and thus the biological response in the
body. For example, inorganic zinc compounds cause an increase in
chromosomal aberrations in rats after intraperitoneal administration.
Studies with intraperitoneal administration were not included in the
evaluation of zinc and its inorganic compounds because the MAK
Commission felt that intraperitoneal injection of high doses used as the
route of administration bypasses the regulation of zinc homeostasis
(Hartwig, 2010a). This does not mean, however, that results obtained
by intraperitoneal administration are generally ignored by the Com-
mission and are therefore never part of the evaluation process.
5. Species-, strain- or organ-specific tumors
A number of different tumor types observed in animal studies have
been shown to lack human relevance because species-specific or strain-
specific organ- or tissue-structures are involved in their development
that have no human equivalent.
5.1. Tumors in species-specific organs
Tumors in organs and/or tissues that are only found in animals but
do not exist in humans generally lack human relevance. Nevertheless,
they can give evidence of a carcinogenic potential. The Zymbal's gland,
Harderian gland or the forestomach in rats are examples of such organs.
However, the induction of tumors in analogous cells and/or tissues in
humans (e.g. squamous cell tumors) is possible (ECHA, 2017). Tumors
in the forestomach of rats and mice are more frequently induced fol-
lowing exposure by oral routes of administration, in particular admin-
istration by gavage. After administration by gavage, very high local
concentrations can be found in the forestomach, which may also lead to
an increase in the exposure time of the respective epithelium. Humans
do not have a forestomach; the esophageal epithelium and the epithe-
lium of the oral cavity and pharynx are, however, possible targets. This
has to be taken into consideration, for example in the case of DNA re-
active substances. Non-DNA reactive, but irritant substances may
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induce severe cytotoxicity, and thus cell proliferation and hyperplasia
after oral administration because of the irritant effect and longer re-
tention time in the forestomach (IARC, 1999c; RIVM, 2004). Forest-
omach tumors induced in rats and mice by the latter route of admin-
istration are, however, considered specific to rodents and without
human relevance because substances are not retained for similar per-
iods of time in any part of the human gastrointestinal tract (RIVM,
2004). Nevertheless, different considerations apply if tumors do not
occur isolated in animal-specific organs; if additional organs are af-
fected in experimental studies, tumors, even though specific to animals,
will add evidence for a carcinogenic potential of the chemical under
consideration.
5.2. Tumors in organs/tissues with a high spontaneous tumor incidence
The high spontaneous incidence of individual tumor entities in a
given animal strain should also be mentioned in this context. Thus, the
late onset of exclusively benign tumors at sites with a high spontaneous
incidence (e.g. the liver) suggests a strain-specific genetically-fixed
tumor susceptibility (U.S. EPA, 2005). A careful case-by-case ex-
amination based on the results on the historical range of tumors in the
respective strains and other relevant information may lead the MAK
Commission to conclude that it has no human relevance.
It should be pointed out that a high background tumor incidence
observed in a certain test animal species or strain often correlates with a
high sensitivity in respective carcinogenicity tests in these animals and
therefore may also provide some advantage. However, the high dose
effects that are discussed above and that are not relevant for classifi-
cation are also particularly effective in the organs of these animals and
induce the observed marked tumor responses. In addition, by its very
nature, it is difficult to prove the statistical significance of tumor in-
duction in cases in which there is a high spontaneous incidence.
Therefore, if the tumors are observed in an animal species with a
high spontaneous incidence of tumors, it is necessary to examine each
case individually. This is especially important if this type of tumor is a
form frequently found in humans, such as lung tumors. In these cases,
further evidence is required to decide on classification or non-classifi-
cation.
5.2.1. Liver adenomas and carcinomas in B6C3F1 mice
A good example is provided by the high spontaneous incidence of
liver tumors and the corresponding high sensitivity for chemical in-
duction of liver adenomas and carcinomas in B6C3F1 mice, often used
in carcinogenicity tests (Haseman et al., 1998; Maronpot, 2009). Un-
treated control animals from 21 inhalation studies carried out by the
NTP (National Toxicology Program) from 1990 to 1997 yielded a per-
centage of liver carcinomas of 21.1% (221 of 1047 investigated ani-
mals, range: 9%–34%) in males and of 13.8% (150/1089, 0%–38%) in
females and a percentage of liver adenomas of 24.6% (257/1047,
4%–48%) in males and of 14.1% (154/1089, 2%–40%) in females
(Haseman et al., 1998). The main reason for the high spontaneous in-
cidence of liver tumors and the high sensitivity for the induction of liver
tumors by chemical substances is genetic predisposition. Thus, genetic
susceptibility loci were identified in sensitive mouse strains such as C3H
or B6C3F1 that are absent in non-sensitive strains such as C57BL
(Drinkwater and Ginsler, 1986; Manenti et al., 1994). In addition, dif-
ferent responses to modifying exogenous factors may play a role in the
varying degree of susceptibility to liver tumor formation of the different
mouse strains (Maronpot, 2009). Assessing the relevance of chemically-
induced liver tumors that occur very frequently and often exclusively in
highly sensitive, but not in resistant, mouse strains leads to the question
of how this information is to be applied to humans. Hepatocellular
carcinoma (HCC) are among the most common tumors worldwide.
However, the incidence of HCC is rather low in the absence of known
risk factors that can induce chronic hepatitis such as a hepatitis B and C
virus infection, exposure to aflatoxins and alcohol abuse. Therefore,
with regard to HCC formation, humans appear to be one of the ge-
netically less sensitive species. The tumor suppressor protein p53 may
play a role here. Mutation often renders the TP53 gene inactive in
human HCCs, but not in those of mice. This indicates that its gene
product plays a much more important role in the malignant transfor-
mation of hepatocytes in humans than it does in the sensitive mouse
(Kress et al., 1992).
5.2.2. Lung tumors in rodents
The incidence of spontaneously occurring lung tumors in rodents
also depends upon the species and the strain. The incidence of spon-
taneous and chemically-induced hyperplasia, adenomas and carci-
nomas in the lungs is higher in mice than in rats. The incidence of
spontaneous lung tumors in mice is dependent upon the strain, as is the
incidence of chemically-induced tumors. The incidence of spontaneous
lung tumors in various mouse strains is, in descending order, 82% for
A/J, 47% for SWR/J, 33% for BALB/c, 17% for CBA, 9% for C3H and
3% for C57BL6. The higher sensitivity of mice for lung tumors is caused
by the pulmonary adenoma susceptibility 1 (Pas 1) locus. The varying
sensitivity of the different mouse strains is attributed to a poly-
morphism of the Pas 1 locus. The strain-to-strain differences in the in-
cidence of spontaneous lung tumors are not as striking in rats as they
are in mice. In descending order, the incidences are 1.9% for F344,
1.8% for Lewis, 0.7% for Osborne Mendel, 0.6% for Brown Norway,
0.5% for both Sprague Dawley and Wistar, 0.4% for CD and 0% for
ACI/N. The status of the Pas 1 locus in the rat strains has not yet been
identified.
Genetic predisposition factors playing a critical role in certain
mouse strains are probably of little relevance for humans, even though
lung cancer is very common in humans but mainly caused by well-
known risk factors such as tobacco smoke. However, positive lung
tumor findings in sensitive rodent strains should always be understood
as a warning sign and the MAK Commission has to decide on a case-by-
case basis whether the positive tumor findings have human relevance.
In cases of uncertainty, the substance should be classified in a carci-
nogen category (see also chapter 6.2.4).
5.2.3. Mononuclear cell leukemia in F344 rats
F344 rats have a high spontaneous incidence of mononuclear cell
leukemia, which is also known as “large granular lymphocytic leu-
kemia” (Maronpot et al., 2016). In NTP studies, the spontaneous in-
cidence increased over the years of investigation: the prevalence of
mononuclear cell leukemia in feeding studies in males was 51% in 1997
and 27% in 1990 (in each case with reference to the preceding seven
years), and 28% and 18%, respectively, in females. In addition, spon-
taneous incidences are subject to great variability (Haseman et al.,
1998). Mononuclear cell leukemia is extremely rare in other rat strains
(Maronpot et al., 2016) and has not been observed in mice or hamsters
(Caldwell, 1999). The only human correlate, a very rare and aggressive
form of leukemia, has a different etiology: it is of viral origin (Maronpot
et al., 2016; Thomas et al., 2007). However, the mechanism that leads
to the development of mononuclear cell leukemia in F344 rats is not
known. It is probably not genotoxic (Maronpot et al., 2016). Mono-
nuclear cell leukemia therefore is considered to be a tumor that is
specific to this rat strain and as such, without human relevance
(Caldwell, 1999; Maronpot et al., 2016).
6. Assessment of benign tumors
When assessing the relevance of tumor findings in animal studies,
one issue that needs to be addressed concerns how benign tumors and
tumor precursors such as preneoplastic liver foci are to be judged. One
of the decisive factors in this context is whether only adenomas were
induced under experimental conditions, or if they were found in com-
bination with carcinomas. Another factor that needs to be taken into
consideration is the likelihood of the respective adenomas progressing
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to malignancy in different tissues. The following paragraphs first dis-
cuss the approaches taken by other organizations.
6.1. Assessment by other organizations
According to the CLP classification criteria of the European
Chemicals Agency (ECHA, 2017), the NTP (National Toxicology Pro-
gram; Huff and Haseman, 1991), the Preamble of the IARC (Interna-
tional Agency for Research on Cancer; IARC, 2006) and the guidelines
of the U.S. EPA (U.S. Environmental Protection Agency; U.S. EPA,
2005), adenomas play a key role in the classification of a substance as a
carcinogen even in case a substance was only found to induce adenomas
in animal experiments and no carcinomas it may be classified as a
carcinogen. However, all organizations emphasize the importance of
assessing each substance individually if only adenomas and no carci-
nomas are observed in animal studies.
6.1.1. ECHA
The CLP classification criteria developed by ECHA (2017) consider
adenomas when assessing whether substances need to be assigned to a
category of carcinogens. In general, any substance that induces ade-
nomas or carcinomas fulfills the criteria for classification as a carci-
nogen. If a substance induces only adenomas in animal studies, it is
generally classified in the category of “suspected carcinogens” (Cate-
gory 2, CLP Annex I, 3.6.2.2.3). If a substance induces carcinomas in
animal studies, it meets the criteria for Category 1B. However, even
substances causing only benign tumors may be suspected of causing
cancer if the observed tumors could potentially develop into carci-
nomas. Some benign tumors, such as brain tumors, present sufficient
cause for concern by themselves even without knowing more about
their malignant potential because they can cause mortality without
developing into carcinomas.
6.1.2. NTP
In publications of the NTP, it was concluded that substance-induced
neoplasia is an important toxicological indicator of a chemical's carci-
nogenic potential in rodents and should be made an integral part of the
overall weight-of-the-evidence evaluation process (Huff et al., 1989).
Another publication emphasized the relevance of adenomas in the as-
sessment of carcinogenicity because, although 3.5% of the evaluated
substances induced only adenomas, these were shown to have the po-
tential to progress to malignant carcinomas. Of 143 substances in-
vestigated by the NTP in 524 long-term studies, 81 showed neoplastic
responses in one or more of the studies and were therefore assessed to
be carcinogenic. Of the 81 studies that were evaluated as “positive”,
carcinomas were reported in 60 (74%) and the almost exclusive oc-
currence of benign neoplasms in 16 (20%). However, there was sup-
porting evidence of a carcinogenic process because isolated carcinomas
were observed in the same organ. Another five studies (6%) were found
to be “positive” based on the occurrence of benign neoplasia alone. This
is equivalent to 3.5% of the 143 substances tested. In contrast, of 200
substances that were evaluated by the NCI (National Cancer Institute),
only 2 (1%) were evaluated as “positive” based on benign tumors (Huff
and Haseman, 1991).
6.1.3. IARC
According to the Preamble of the IARC (2006), substances are
classified as carcinogenic if adenomas found in animal studies can be
defined as carcinoma precursors with certainty. This applies if a study
were to find both adenomas and carcinomas in the same organ and cell
type. In this case, the incidences of adenomas and carcinomas are to be
assessed together/in combination. The IARC also emphasizes the need
to assess the biological plausibility of preneoplastic findings. In the
absence of malignancy risk data, the occurrence of only adenomas can
also be evaluated as limited evidence of carcinogenicity (IARC, 2006).
6.1.4. U.S. EPA
The U.S. EPA (2005) clearly favors a case-by-case assessment if only
adenomas are observed in animal studies. According to the U.S. EPA,
incidences of benign and malignant tumors of the same cell type are to
be considered separately but may be combined when scientifically de-
fensible. In the assessment of adenomas, a wide range of possibilities
needs to be considered: for example, benign tumors can also lead to
serious health problems and critically impair organ function, such as in
the case of a brain tumor. Adenomas are to be considered significant
indicators of carcinogenicity and there is a need for further testing
especially in the case when they are observed in a short-term test
protocol and no conclusions can be made about a possible later pro-
gression to malignancy. Knowledge of the mechanism of action asso-
ciated with an adenoma may aid in the interpretation of other tumor
responses associated with the same substance. In other cases, observa-
tion of a benign tumor response alone may not be predictive for the
occurrence of malignant tumors when other sources of evidence show
no suggestion of carcinogenicity for this substance.
6.1.5. Summary
As long as the data do not prove otherwise, the IARC, ECHA and
NTP assume the worst case and interpret adenomas as precursors of
malignant tumors. Only the U.S. EPA considers the possibility that
benign tumors may not represent a significant health risk.
6.2. Assessment of the risk of malignant transformation of preneoplastic
and neoplastic lesions including adenomas
This chapter discusses how to evaluate the risk that different types
of preneoplastic and benign neoplastic lesions including adenomas
transform into malignant populations and whether there are adeno-
matous changes that do not need to be considered as precursors of
carcinomas.
6.2.1. Hepatocellular preneoplasms and benign neoplasms
The liver is an important target organ in many carcinogenicity
studies in rodents. However, the type of proliferative lesion and its
human relevance needs to be considered. The assessment should take
into account not only the late stages of the different types of hepato-
cellular lesions but also the early ones (Thoolen et al., 2012).
Focal nodular hyperplasia is a benign tumor of the liver that does
not have malignant potential. With a prevalence of 3%–5% in the
Western population, it is the second most common benign liver change
after cysts and haemangiomas (Bastati-Huber et al., 2015). Differ-
entiating focal nodular hyperplasia from hepatocellular adenoma has
proven to be a diagnostic challenge (Bastati-Huber et al., 2015; Thoolen
et al., 2012). Focal nodular hyperplasia is rarely observed in animal
studies (Thoolen et al., 2012).
Hepatocellular adenoma is a benign epithelial tumor of the liver.
However, unlike other benign liver tumors, it has a high potential for
malignancy (Dietrich et al., 2005). The hepatocellular adenoma is the
third most common benign neoplasm in humans; young women that
take oral contraceptives account for 85% of the patients. The histolo-
gical characteristics of hepatocellular adenoma are similar in rats and
humans. Unlike focal nodular hyperplasia, hepatocellular adenomas are
monoclonal and have a correspondingly high risk of malignancy
(Thoolen et al., 2012). The risk of malignancy is about 10%; however,
reference is also made to the difficulties inherent in making a differ-
ential diagnosis with respect to hepatocellular carcinomas (Dietrich
et al., 2005; Dokmak et al., 2014). Hepatocellular adenomas with
mutations in CTNNB1 (coding for β-catenin) also have an increased risk
of malignancy. Hepatocellular carcinomas in both rats and humans
exhibit the malignancy patterns and histopathological characteristics
typical of these tumors (Thoolen et al., 2012).
In rats, preneoplastic foci are considered to be precursors of he-
patocellular adenomas and carcinomas; however, neoplasms do not
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develop from all foci. The rat counterparts of the human classifications
“large cell” and “small cell dysplasia”, which are considered to be in-
dicative of a malignant progression to hepatocellular carcinoma, are
basophilic, eosinophilic and clear cell foci. The malignant potential of
foci of different genotypes and phenotypes varies. As an example, the
malignant potential of basophilic foci is greater than that of eosino-
philic foci (Ito et al., 1995; Marsman and Popp, 1994). Liver cell foci
occur spontaneously in older rats and other rodents. For example, the
spontaneous incidence in two-year-old F344 rats was almost 100%. The
foci can be induced by exposure to liver carcinogens, which shortens
the latency period for tumor formation.
Liver cell dysplasia is often observed in cirrhotic livers and at-
tributed with precarcinogenic properties. This means that its cytolo-
gical properties are very similar to those of hepatocellular carcinomas.
This is still a matter of controversy in the case of large-cell and small-
cell dysplasia, but both have been considered to be precancerous lesions
(Thoolen et al., 2012).
Hepatocarcinogenesis shares similarities between humans and ani-
mals, in particular in terms of early cellular and molecular markers. As
an example, many similarities were found when the gene expression
patterns of CTNNB1-mutated liver tumors were analyzed in mice and
humans (see for example Stahl et al., 2005; Unterberger et al., 2014).
Hepatocellular tumors display marked heterogeneity in humans, in
particular during the late stages of tumor progression; this is not as
evident in test animals. There is no universal molecular mechanism of
hepatocarcinogenesis that is valid for humans, rats and mice (Maronpot
et al., 2004). For example, tumors differ in their etiology in rodents and
humans (Grisham, 1997; Maronpot et al., 2004). There are also marked
differences in the mutation frequency of genes associated with tumor
formation. H-Ras mutations, for instance, often lead to tumor formation
in the livers of mice, but are much less frequently observed in hepa-
tocellular carcinomas in rats and very rarely in humans (Grisham,
1997).
Mutagenic tumor initiating agents requiring metabolic activation
may no longer be toxic in adenomas because of a lack of activating
enzymes in these lesions (Buchmann et al., 1987). Therefore, the me-
chanism that accelerates malignant progression from adenomas to
carcinomas can probably not be explained by the induction of muta-
tions by a given carcinogen exposure. In the development of hepato-
cellular carcinomas, both genetic changes and the epigenetic activation
of oncogenes or inactivation of tumor suppression genes are important
mechanisms of tumor formation (Kanda et al., 2015; Tischoff and
Tannapfel, 2008).
Even though the significance of preneoplastic lesions in the livers of
rats and humans as carcinoma precursors and their human relevance
are not completely understood (Thoolen et al., 2012), they can be
considered biomarkers for carcinogenic activity. Kunz et al. were able
to show that a quantitative evaluation of ATPase-deficient, pre-
neoplastic foci in the livers of rats treated with N-nitrosomorpholine or
N-nitrosodiethylamine can quantitatively predict the formation of
adenomas and carcinomas in this organ (Kunz et al., 1983). Therefore,
at the very least, substance-induced preneoplastic foci in the liver of
rodents are a warning sign. However, if found as isolated lesions, they
generally do not lead to classification into a carcinogen category.
6.2.2. Papillomas in the mouse skin initiation-promotion model
The MAK Commission has evaluated the significance of papilloma
formation in the initiation-promotion model of the dorsal skin of mice
for the classification of carcinogenic substances. They arrived at the
conclusion that a tumor-promoting effect in mouse skin, which is in-
duced by a nonspecific mechanism such as chronic irritation and only
occurs at very high doses that lack human relevance, is not considered
predictive of the development of skin tumors in humans (Schwarz et al.,
2015). Oleic acid is one such example: In 2001, the MAK Commission
classified the substance in CC 3A (Greim, 2002a) because of its tumor-
promoting effect, but, following re-evaluation in 2016, withdrew it
from this category (Hartwig, MAK Commission, 2016d).
The development of papillomas in experimental studies is largely
restricted to the mouse. In other species such as rats or minipigs pa-
pillomas are only minimally or not induced at all. Likewise, human skin
does not react to the application of chemical substances or to irritation
by forming skin papillomas. As precancerous lesions (carcinoma in situ,
actinic keratosis) and squamous cell carcinomas of the human skin do
not develop via precursors of papillomas, there is no direct analogy
between papillomas of the mouse skin and actinic keratosis.
Papillomatous changes of the skin are quite common in humans and are
often caused by viruses. However, there is no direct equivalence to
chemically induced papillomas in the mouse skin because no progres-
sion into malignant lesions are known in humans after exposure to
chemical noxa (Schwarz et al., 2015).
6.2.3. Fibroadenomas and adenocarcinomas in the mammary glands of rats
Tumors of the mammary glands in rats fall into different categories.
As in humans, fibroadenomas in the mammary glands of rats are benign
tumors that are made up of highly differentiated epithelial fractions and
fibrous connective tissues. In most rat strains, the spontaneous in-
cidence of fibroadenomas in females is between 20% and 40%. The
period with the highest risk is between 31 and 36 months; in older rats,
the incidence decreases again. In humans, fibroadenoma is the most
common benign tumor in women of childbearing age. It most fre-
quently forms during adolescence, pregnancy and menopause, i.e.
during periods marked by relatively constant estrogen stimulation,
while fibroadenomas form to a lesser degree in women whose cycles are
characterized by frequent fluctuations in hormone levels (Russo, 2015).
Fibroadenomas are not considered to be precancerous lesions in rats
and humans. However, adenocarcinomas that did arise in fi-
broadenomas were considered as separate (Rudmann et al., 2012).
Substance-induced tumors in the mammary glands of rats are gen-
erally hormone-dependent adenocarcinomas (Russo, 2015); these are
considered relevant for classification. The frequency of adenocarci-
nomas induced by genotoxic carcinogens such as 7,12-dimethylbenz[a]
anthracene, N-nitrosomethylurea and N-ethyl-N-nitrosourea can be
modulated by various factors such as reproductive status, hormone
treatments, feed, and the dose and time of carcinogen treatment
(Rudmann et al., 2012). Initiation primarily takes place in the epithe-
lium of the terminal end buds as they are developing into alveolar buds
and terminal ducts. These structures are considered to be the counter-
parts of the terminal ductal lobular units of humans (Russo, 2015).
6.2.4. Lung tumors in rats and mice
In an assessment of substances evaluated by the IARC, the lungs
were found to be the organ most frequently affected by tumors in both
humans and rats (Krewski, 2014). Rodent lung tumors are pre-
dominantly bronchioloalveolar adenomas and carcinomas and follow a
progressive continuum from hyperplasia to adenoma to carcinoma.
Histologically, rodent lung tumors are very homogeneous. In contrast,
human pulmonary carcinomas have a high degree of histologic het-
erogeneity and include squamous epithelial cells, neuroendocrine,
mucinous and sarcomatoid cells, and multiple cell combinations. In
addition, they exhibit a higher metastatic rate, higher stromal response,
aggressive clinical behavior and lack of a clear continuum of pro-
liferative lesions. Rodent lung tumors originate primarily in the per-
ipheral lung and involve the distal bronchioles and alveolar acini, while
bronchial or proximal bronchiolar tumors are very rare. In humans, the
majority of lung tumors are caused by tobacco smoking. Most arise
centrally or within the bronchi and are primarily squamous cell carci-
nomas or small cell carcinomas. Lung tumors in humans are categorized
into two large groups: non-small cell lung cancer, which accounts for
80% of all cases of lung cancer, and small cell lung cancer. Non-small
cell lung cancer comprises adenocarcinomas, squamous cell carci-
nomas, adenosquamous carcinomas, large cell carcinomas and sarco-
matoid carcinomas. About 18% of lung tumors may be categorized as
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malignant small cell lung tumors that have a neuroendocrine mor-
phology and a very high metastatic potential. The remaining 2% are
neuroendocrine tumors consisting of typical and atypical carcinoids
(Pandiri, 2015). Pulmonary neuroendocrine tumors have not been
found in rodents.
Atypical adenomatous hyperplasia in humans bears histologic si-
milarities to alveolar hyperplasia in rodents and is therefore thought to
be a precursor lesion for peripheral lung adenocarcinomas. In addition,
an analysis of global gene expression changes in the lung tumors of
humans and mice found a high degree of resemblance (Bonner et al.,
2004; Pandiri et al., 2012; Pandiri, 2015; Stearman et al., 2005). These
data suggest that lung tumors in mice are morphologically and mole-
cularly similar to adenocarcinomas in humans and thus of relevance to
humans. Therefore, adenocarcinomas in the lungs of rodents are in
general relevant for classification.
7. Examples of substances
The following gives several examples of substances that were the
subject of extensive discussion by the MAK Commission with regard to
the human relevance of tumors observed in animal studies. All sub-
stances have a threshold for tumor induction; in some cases, carcinomas
only occurred at very high doses. In the subsequent Sections 7.1 and
7.2, the substances are categorized into those that were ultimately
classified in CC 4 and those that did not require classification, respec-
tively. For an overview see Table 2. An overview of the carcinogenicity
classifications by other organizations is given in Table 3.
7.1. Examples of substances classified in Carcinogen category 4
7.1.1. Nitrobenzene
Nitrobenzene induces adenomas and in some cases also carcinomas
in the liver, kidneys and thyroid gland of rats and in the lungs and
mammary glands of mice after exposure to high concentrations by in-
halation (Hartwig, MAK Commission, 2017).
Arguments for classification:
• Tumors in two species and five organs.• A mechanism of action that allows for the derivation of a threshold
value (required for classification in CC 4), namely cytotoxicity and
formation of ROS at higher doses.• Structurally related to substances for which extensive data on car-
cinogenicity is available.• Evidence of secondary genotoxicity in the high dose range.
Arguments against classification:
• Tumors observed in species/strains that show particular suscept-
ibility in the target organs (thyroid gland/rat, kidneys/rat, lung/
mouse; see also Section 4.4. and 5).• Tumors observed in species/strains that have an increased sponta-
neous incidence for these tumors (mammary glands/mouse).• Tumor formation in the range of “nonspecific toxicity” at very high
doses that exceed the MTD.
Conclusion: Nitrobenzene is cytotoxic in different organs and in
different species. Damage to the erythrocytes and the formation of su-
peroxide radicals is observed. Nitrobenzene has the same metabolite
(phenylhydroxylamine) as aniline (Hartwig, 2009b), which is re-
sponsible for the formation of ROS and tumor formation results from
long-term damage. Based on the overall evaluation of the tumors, its
non-linear dose–response relationship, and since genotoxicity only
plays a subordinate role (Hartwig, 2009b), nitrobenzene has been
classified in CC 4.
7.1.2. o-Phenylphenol (OPP) and sodium OPP
OPP induces liver tumors in male B6C3F1 mice and bladder tumors
in male F344/DuCrj rats (Hartwig, MAK Commission, 2016b, available
only in German).
Arguments for classification:
• Presence of carcinomas in two species: male mouse/liver, male rat/
urinary bladder.• A mechanism of action that allows for the derivation of a threshold
value (required for classification in CC 4), namely bladder tumors in
male rats in the saturation range of metabolism.• Unanswered questions concerning the human relevance and extra-
polation of findings from rat studies to humans because the induc-
tion mechanism of cell proliferation in the bladder is not fully un-
derstood.
Arguments against classification:
• Carcinomas in a mouse strain (B6C3F1) that has been shown to have
a high spontaneous incidence of liver tumors.• Bladder tumors in rats which show increased susceptibility for this
tumor type.• Mechanism identified, but with no or questionable human re-
levance: bladder tumors in male rats in the saturation range of
Table 2
Overview of examples described in Section 7.
Substances classified in CC 4 Arguments for and against classification
Nitrobenzene against: tumors in sensitive organs/species, only isolated cases of carcinomas at the level of the MTD
for: cytotoxicity and damage to erythrocytes (phenylhydroxylamine), reactive oxygen species, tumor formation resulting from chronic damage,
mechanism of action with human relevance
o-Phenylphenol against: bladder tumors in male rats in the saturation range of metabolism with overloading of detoxification via the sulfate conjugate;
urothelium markedly less sensitive in humans than in male rats
for: unanswered questions concerning the human relevance and extrapolation of the findings to humans because the mechanism of cell
proliferation in the bladder is not fully understood
N,N-Dimethylformamide against: hepatocellular adenomas, carcinomas and hepatoblastomas only occur at doses at which necrosis is also induced
for: liver carcinogenicity in rats and mice resulting from liver cell necrosis (causes rapid regenerative proliferation of hepatocytes) after long-term
exposure to N,N-dimethylformamide or its metabolites
Substances not classified
Imazalil against: thyroid adenomas and carcinomas induced by a compensatory effect (induction of glucuronosyltransferases, followed by decreased T4
and increased TSH levels); liver adenomas in the range of the MTD only in the case of marked hepatotoxicity
2-Ethylhexanol against: liver carcinomas in female mice only after MTD exceeded by toxic effects on the liver
Atrazine against: no genotoxicity; early development of adenocarcinomas in the mammary gland attributed to premature aging of the reproductive system
of female Sprague Dawley rats; not relevant to humans
Butoxyethanol against: liver tumors in mice and pheochromocytomas in rats indirectly caused by hemolysis; humans are significantly less sensitive to this effect
than rats or mice. This species difference is so great that the level of exposure required to induce tumors cannot be reached because of the limiting
effect of irritation
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metabolism with overloading of detoxification via the sulfate con-
jugate; moreover, the sensitivity of the human urothelium is mark-
edly lower. Cell proliferation in the bladder of male rats only at
doses that induced marked cytotoxicity.• “Confounding through excessive toxicity”: tumorigenic effects only
at very high doses that exceed the MTD.• Metabolism saturated (deactivation saturated, other metabolites).• No genotoxicity; clastogenic only at high doses.
Conclusion: Cytotoxicity in combination with species-specific and
sex-specific factors is considered to be the cause of the tumors observed
only in the saturation range of metabolism after exposure to OPP and
sodium OPP. A contributing factor is the high sensitivity of the urinary
tract in male rats. These bladder tumors are not relevant to humans as
long as inflammatory or reactive changes in the urothelium are not
induced. However, in the case discussed here, some questions con-
cerning the human relevance and extrapolation of findings in male rats
to humans remain because the mechanisms underlying induction of cell
proliferation is not fully understood (see also Section 4.4.2). Therefore
the compound was classified in CC 4.
7.1.3. N,N-dimethylformamide
N,N-Dimethylformamide induced hepatocellular carcinomas in
male rats of the high exposure group and in mice of all exposure groups
after long-term exposure by inhalation (Hartwig, MAK Commission,
2016e).
Arguments for classification:
• Hepatocellular carcinomas in male rats and in mice.• Liver also a target organ of the toxic effect in humans.• A mechanism of action that allows for the derivation of a threshold
value (required for classification in CC 4): tumors are induced
subsequent to induction of liver cell necrosis and regenerative pro-
liferation of hepatocytes caused by N,N-dimethylformamide, or its
metabolites N-methylformamide and methyl isocyanate.
Arguments against classification:
• Not genotoxic• Tumors (hepatocellular adenomas and carcinomas, and hepato-
blastomas) occur only at doses that induce necrosis.
Conclusion: N,N-dimethylformamide has no genotoxic potential.
Long-term studies have shown that liver tumors are only observed
following the induction of chronic, regenerative toxic effects. The tu-
mors are considered to be a result of chronic damage and only occur
after exposure at a level that leads to necrotic changes. Therefore the
compound was classified in CC 4.
7.2. Examples of substances not classified in a carcinogen category
7.2.1. Imazalil
Imazalil causes hepatocellular adenomas and follicular adenomas
and carcinomas of the thyroid gland in male rats. It also induces ade-
nomas in the liver of male mice, but without a clear-cut dose-response
relationship (Hartwig, 2014c).
Arguments for classification:
• Follicular adenomas and carcinomas of the thyroid gland in male
rats and liver adenomas in male rats and mice.
Arguments against classification:
• Absence of liver carcinomas (only adenomas observed) in male rats
and mice (see Section 6.2).• Lack of a dose-response relationship with respect to liver adenomasTab
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in mice; mouse strain used (Swiss) characterized by a high sponta-
neous incidence of liver tumors (see Section 5.2). No significant
increase in thyroid tumors in rats; significant increase only when
adenomas and carcinomas are combined for analysis (Bartsch et al.,
2018; see Section 4.4.4).• Liver adenomas only at marked hepatotoxicity and at the level of the
MTD; imazalil induces liver enzymes in rats and mice and leads to
liver damage and regenerative proliferation.• Development of thyroid tumors in rats via a compensatory effect
(induction of glucuronosyltransferases, followed by decreased T4
and increased TSH levels).• Not genotoxic in vivo.
Conclusion: Tumors induced by imazalil are not due to a genotoxic
effect. The substance induces liver enzymes and leads to degenerative
liver damage. No liver adenomas are induced in the absence of hepa-
totoxicity. Liver carcinomas do not develop even at the level of the
MTD. Only the combined incidence of adenomas and carcinomas in the
thyroid gland is increased. The latter is caused by the induction of
glucuronosyltransferases and thus decreased T4 and increased TSH
concentrations. As long as the exposure remains at imazalil con-
centrations that are low enough not to affect T4 or TSH concentrations,
no thyroid tumors are expected. In addition, humans are less sensitive
to disturbances in thyroid hormone homeostasis than rats (see also
Section 4.4.4) Therefore, imazalil was not classified in a carcinogen
category.
7.2.2. 2-Ethylhexanol
2-Ethylhexanol induces liver carcinomas only in female B6C3F1-
mice (Greim, 2003b).
Arguments for classification:
• Liver: focal hyperplasia and isolated carcinomas in female mice.
Arguments against classification:
• Tumor induction at levels far exceeding the MTD (15 of 50 animals
died during the experiment or were in a moribund state).• Postulated mechanism of action: peroxisome proliferator, metabo-
lite of Bis(2-ethylhexyl) phthalate (DEHP), a well-documented ac-
tivator of the peroxisome proliferator activated receptor α (PPARα).
However, a (PPARα)-mediated effect is not plausible since tumors
did not occur in both sexes. Therefore, “unspecific” hepatotoxicity
likely to be the cause of tumor formation.• Not genotoxic.
Conclusion: Isolated liver carcinomas only in female mice at levels
that far exceed the MTD. Moreover, no genotoxicity observed.
Therefore, 2-ethylhexanol was not classified in a carcinogen category.
7.2.3. Atrazine
In female Sprague Dawley rats, atrazine leads to a decreased la-
tency period and to an increased incidence of adenocarcinomas in the
mammary glands. No breast tumors were observed in F344 rats or mice
at the same dose (Hartwig, 2013, available only in German).
Arguments for classification:
• Adenocarcinomas of the mammary gland in female Sprague Dawley
rats.
Arguments against classification:
• Tumors only in Sprague Dawley rats, but not in F344 or Long Evans
rats.• Rat strain-specific differences known in the effects on the hypotha-
lamus-pituitary-gonad axis.
• Mechanism of action: decline and loss of the LH (luteinizing hor-
mone) surge, increase in estrogen and prolactin levels leading to
premature aging of the reproductive system followed by formation
of adenocarcinomas of the mammary gland.
Conclusion: Atrazine has no genotoxic effect. The early induction
of adenocarcinomas in the mammary gland in female Sprague Dawley
rats is caused by premature aging of the reproductive system. This
mechanism of action is not relevant to humans because reproductive
aging progresses differently in humans (exhaustion of the ovarian fol-
licle, decrease in estrogen and prolactin levels). Therefore, atrazine was
not classified in a carcinogen category.
7.2.4. Butoxyethanol
Following chronic inhalation, 2-butoxyethanol induced benign and
malignant pheochromocytomas in the adrenal medulla in female F344
rats, liver cell carcinomas and hemangiosarcomas in male B6C3F1 mice
and squamous cell papillomas, associated with a concentration-depen-
dent increase in tumors and epithelial hyperplasia in the forestomach of
female B6C3F1 mice (Hartwig, MAK Commission, 2018).
Arguments for classification:
• Tumors in two species and three organs.• Dose-dependent induction of tumors.
Arguments against classification:
• B6C3F1 mice exhibit a high spontaneous incidence of hepatocellular
tumors (see also Section 5.2.1).• Forestomach tumors in rats are not relevant to humans because the
retention period in the human stomach is shorter, the gastric mucosa
protects the stomach from irritants, and the localization of the en-
zymes that are necessary for acid production is not the same as in
the forestomach of rodents.• Mechanism of action: liver tumors in mice and pheochromocytomas
in rats are very likely caused by hemolysis induced by butox-
yethanol and butoxyacetic acid (the active metabolite). Humans are
markedly less sensitive than rats and mice for hemolysis and the
hemosiderosis in the liver that is caused by hemolysis. In human
volunteers exposed to a saturated vapor atmosphere (reflecting in-
halative plus skin exposure), butoxyacetic acid had only a minimal
hemolytic effect.• Not genotoxic.
Conclusion: Forestomach tumors in mice induced by the non-gen-
otoxic substance 2-butoxyethanol are not relevant to humans. The liver
tumors in mice and the pheochromocytomas in rats were very likely
caused by the induction of hemolysis. Humans are markedly less sen-
sitive than rats and mice for hemolysis and the hemosiderosis in the
liver that is caused by hemolysis. The species differ so greatly in this
respect that the level of exposure necessary for tumor formation in
humans is not achieved because of the limiting effects of irritation,
which limits the exposure at the workplace. For this reason, 2-butox-
yethanol was withdrawn from CC.
8. Catalogue of criteria
The following criteria are used by the MAK Commission to decide
whether a substance being assessed should or should not be classified in
a carcinogen category:
Arguments FOR classification:
• Human data, in particular if dose-response relationships can be
proven (CC 1).• Genotoxicity (CC 4 only in the case that genotoxicity plays a minor
role).
B. Laube, et al. Regulatory Toxicology and Pharmacology 108 (2019) 104444
13
• Tumors in several organs, several species, via several routes of ad-
ministration, irrespective of sex.• Mechanism of tumor formation in the animal studies has human
relevance and demonstrates a clear dose-response relationship.
Special case: a mechanism of action that enables the derivation of a
threshold value (e.g. hormonal effect, physiological regulatory me-
chanisms) for tumor induction allows classification in CC 4.• Occurrence of rare tumors definitely induced by the substance.• Structural relationship with substances for which carcinogenic ef-
fects have been demonstrated and for which extensive carcino-
genicity data are available (Suspicion for carcinogenicity leading to
classification in CC 3B)• Induction of exclusively adenomas, but with a high risk of malignant
progression to carcinomas (Suspicion for carcinogenicity leading to
classification in CC 3B).
Arguments AGAINST classification:
• No genotoxicity (does not apply to CC 4).• Species-/strain-specific tumors that lack human relevance (e.g. in-
duction via pathways specific to that species); i.e. mechanism
known and without human relevance (see Section 4.2, 4.3, 5.1).• Carcinogenic responses in species/strains with high susceptibility
towards development of the tumors in question and an increased
spontaneous incidence of these tumors (see Section 5.2).• Carcinogenic effects observed exclusively at very high doses that are
in the range of the MTD (confounding effects mediated through
excessive toxicity (see Section 4.1).• Carcinogenic effects observed in animal studies at exposure levels
that are much higher than would be tolerated by humans (requires
examination of the exposure conditions in the animal studies, e.g.
route of administration, duration and frequency, and their relevance
to the conditions at the workplace).• Tumor occurrence only at the application site in very sensitive test
systems if target organs lack human relevance (see Section 5.1).• Saturated metabolism (deactivation saturated, other metabolites) if
this cannot occur in humans under realistic exposure conditions (see
Section 4.2).• Adenomas without a known potential for progression to malignancy
(e.g. papillomas of the skin) (see Section 6.2.2).
9. Conclusions
When evaluating the safety of substances that are relevant for the
workplace, the challenge is to draw the line between either their clas-
sification in one of the categories for carcinogens or, alternatively, no
classification as carcinogen. As there are only data from animal studies,
but no human data available for the majority of the substances, the
interpretation of these data and the question of their extrapolation to
humans play an essential role in the assessment process. As animal
studies are often carried out under “extreme conditions” (of particular
importance in this context being the exposure to very high doses close
to or at the MTD), the relevance of these findings for humans under
realistic exposure conditions needs to be critically examined in each
individual case.
For this reason, the MAK Commission assesses tumors induced in
animal studies as follows:
Mechanism of tumor formation:
1. In the case of a direct genotoxic effect (e.g., the substance itself or
one of its metabolites causes damage to the genetic material), any
tumor resulting from this effect in animal studies should always be
evaluated as having human relevance. Accordingly, the substance is
to be classified in one of the categories for carcinogens. The same
applies in the case of an indirect genotoxic effect (e.g., the substance
or one of its metabolites leads to the formation of reactive
intermediates, such as reactive oxygen species, which then cause
damage to the genetic material, or impair the repair of (endogenous)
DNA damage or influence the accuracy of DNA polymerases). These
are assessed as having human relevance if they are not limited to
extremely high doses not relevant to human exposures (see below).
In the case of substances that have a nongenotoxic mechanism of
action, a case-by-case evaluation is required to determine whether
the postulated mechanism of tumor induction is relevant to humans.
If the matter of human relevance cannot be decided with certainty,
the substance should be classified in one of the categories for car-
cinogens.
2. High dose effects: If tumors only occur in animal studies at ex-
tremely high doses, generally in the range of the MTD, then the next
step is to examine whether the regenerative processes that are in-
duced in the target organ by toxicity or indirect genotoxic effects are
the cause of the carcinogenic effect and would not be expected to
occur at lower doses. Likewise, mechanisms may become effective
(e.g. precipitates in the target organ) in the high dose range that can
reliably be ruled out at the lower doses that are relevant to humans.
Furthermore, in isolated cases, acute toxic effects such as irritation
limit the dose at a sufficient margin, ensuring that very high con-
centrations will definitely not be reached in the target organs in
humans. In these cases, the substance is generally not classified in
one of the categories for carcinogens. But if it is classified,
Carcinogen Category 4 is the category of choice in most cases.
3. Species-specific mechanisms of tumor formation that are definitely
not relevant to humans do not lead to classification, one such ex-
ample being tumors that are induced in the renal tubules of male
rats by an α2u-globulin-mediated mechanism.
4. In certain cases, it is necessary to establish whether the species
(animal/human) differences in the activating/detoxifying metabo-
lism of a substance which is carcinogenic in animal studies are
quantitatively so pronounced that all human relevance can be ruled
out. If these questions cannot be answered with certainty, the sub-
stance is classified in one of the categories for carcinogens.
Frequency and severity of the carcinogenic effect:
• Tumor findings in animal experiments gain weight if several organs
are affected and/or tumors occur in several species. Their frequency
is also a criterion for classification. Under certain circumstances,
historical control incidences can be included in the evaluation. In
each individual case, all arguments for and against have to be
weighed against each other before making the decision to classify or
refrain from classifying a substance. Therefore, it is not possible to
develop a general guideline for all instances. The following points
should be considered in the evaluation: Are the species/strains in
which the tumors were observed known to have a high spontaneous
incidence of these tumors in the target organ? Do the tumors only
occur in highly sensitive strains? If so, classification may not be
necessary in a case by case evaluation, given that the mechanism of
tumor induction has been proven not to be relevant to humans.
Tumor precursors and benign tumors:
• If tumor precursors such as preneoplastic liver foci are the only
response induced in animal studies, classification is not necessary. If
they are observed together with adenomas, this can be considered
further evidence of a potentially malignant response in the target
organ. If both adenomas and carcinomas are observed in the target
organ, these are in general assessed together. If there is possibility of
human relevance, the substance is classified in one of the carcinogen
categories.• Tumors in organs that are not found in humans are considered to be
indicators of potential carcinogenic activity, but do not generally
lead to classification. Tumors that occur in humans but, unlike in
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animals, are not caused by exposure to chemicals (e.g. skin pa-
pillomas), are in general not relevant for classification.
The MAK Commission uses this guidance document to make a well-
founded and reasonable assessment of the possible carcinogenic risk for
humans posed by the substance being evaluated under exposure sce-
narios that occur at the workplace. The assessments are to be made on a
case-by-case basis, taking into consideration a weight-of-evidence
evaluation process. If both human data and findings from animal stu-
dies are available, these should be analyzed together after examining
the plausibility of causation according to Bradford-Hill criteria. As a
rule, human data are weighted more heavily than findings from animal
studies. The results of the assessments are documented in detail.
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Annex
Category 1 Substances that cause cancer in man and can be as-
sumed to contribute to cancer risk. Epidemiological studies provide
adequate evidence of a positive correlation between the exposure of
humans and the occurrence of cancer. Limited epidemiological data
can be substantiated by evidence that the substance causes cancer
by a mode of action that is relevant to man.
Category 2 Substances that are considered to be carcinogenic for
man because sufficient data from long-term animal studies or lim-
ited evidence from animals studies substantiated by evidence from
epidemiological studies indicate that they can contribute to cancer
risk. Limited data from animal studies can be supported by evidence
that the substance causes cancer by a mode of action that is relevant
to man and by results of in vitro tests and short-term animal studies.
Category 3 Substances that cause concern that they could be car-
cinogenic for man but cannot be assessed conclusively because of
lack of data. The classification in Category 3 is provisional.
Category 3 A Substances that cause cancer in humans or animals or
that are considered to be carcinogenic for humans for which the
criteria for classification in Category 4 or 5 are in principle fulfilled.
However, the database for these substances is insufficient for the
establishment of a MAK or BAT value.
Category 3 B Substances for which in vitro or animal studies have
yielded evidence of carcinogenic effects that is not sufficient for
classification of the substance in one of the other categories. Further
studies are required before a final decision can be made. A MAK or
BAT value can be established provided no genotoxic effects have
been detected.
Category 4 Substances that cause cancer in humans or animals or
that are considered to be carcinogenic for humans and for which a
MAK value can be derived. A non-genotoxic mode of action is of
prime importance and genotoxic effects play no or at most a minor
part provided the MAK and BAT values are observed. Under these
conditions no contribution to human cancer risk is expected. The
classification is supported especially by evidence that, for example,
increases in cellular proliferation, inhibition of apoptosis or dis-
turbances in cellular differentiation are important in the mode of
action. The classification and the MAK and BAT values take into
consideration the manifold mechanisms contributing to carcino-
genesis and their characteristic dose-time-response relationships.
Category 5 Substances that cause cancer in humans or animals or
that are considered to be carcinogenic for humans and for which a
MAK value can be derived. A genotoxic mode of action is of prime
importance but is considered to contribute only very slightly to
human cancer risk, provided the MAK and BAT values are observed.
The classification and the MAK and BAT values are supported by
information on the mode of action, dose-dependence and tox-
icokinetic data.
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